novo semaglutide alzheimer's evoke trial Nordisk's results to be presented at CTAD 2025 semaglutide alzheimer's study GLP-1 Drug

Lee SO, Kuthati Y, Huang WH, Wong CS (2024) Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord

Recent studies and regulatory reviews have examined whether Ozempic and other GLP-1 receptor agonist drugs may carry a significantly increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare optic nerve condition that can cause sudden vision loss and permanent visual impairment

Mechanistic studies linking G6PD-d to cellular processes involved in atherosclerosis G6PD-d impairs vascular homeostasis Nitric oxide (NO) plays an important role in the early development of ASCVD

Reviewer: Chiamaka N